Effect of long-term spleen dialysate (Solcosplen) administration on plasma lipids and lipoproteins in early postmenopausal women.
A total of 46 early postmenopausal women with elevated levels of total cholesterol, triglycerides, low-density lipid (LDL) cholesterol and lowered high density lipoprotein cholesterol (HDL) cholesterol was treated with spleen dialysate (Solcosplen), 2 x 2 tablets daily for 6 months. Serum estradiol levels rose from 42.3 +/- 15.4 pg/ml to 60.6 +/- 23.6 pg/ml and the Kupperman Index decreased significantly after 6 months of treatment. Also, a significant decrease of total cholesterol, triglycerides, LDL cholesterol, and an increase of HDL cholesterol was observed. The changes showed no correlation with the estradiol concentration and no side-effects were evident. Solcosplen is recommended as a beneficial therapy for women in the early postmenopause.
Milewicz
A
A
Department of Endocrinology, Medical Academy, Wroclaw, Poland.
Teucher
T
T
Schmitz
H
H
D000924:Anticholesteremic Agents / Q000494:pharmacology*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008137:Longitudinal Studies; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D017698:Postmenopause / Q000378:metabolism*; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D013154:Spleen / Q000502:physiology*; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D014020:Tissue Extracts / Q000494:pharmacology*
D000924:Anticholesteremic Agents; D008055:Lipids; D008074:Lipoproteins; C083458:Solcosplen; D014020:Tissue Extracts; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone